Streetbeat News

ABOS

Acumen Pharmaceuticals, Inc.

https://acumenpharm.com

Industry

Biotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Open

2.62

Mkt cap

144M

Volume

296K

High

2.62

P/E Ratio

-2.16

52-wk high

5.09

Low

2.37

Div yield

N/A

52-wk low

2.08

Citigroup analyst David Hoang has initiated coverage on Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy rating and set a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

July 25, 2024 | 9:19 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 11:19 am

In Tuesday's pre-market session, several health care stocks showed significant movement. CareCloud, Syra Health, Vaxart, Sharps Technology, Harrow, and Acumen Pharmaceuticals were among the gainers, with notable increases in their stock prices. Conversely, Scorpius Holdings, Augmedix, Akoya Biosciences, Inotiv, Inspire Veterinary, and Dermata Therapeutics experienced declines. These movements were largely attributed to the release of Q1 earnings reports.

Portfolio Pulse from Benzinga Insights

May 14, 2024 | 12:06 pm

Acumen Pharmaceuticals (NASDAQ:ABOS) reported Q1 2024 GAAP EPS of $(0.25), surpassing the $(0.27) estimate by 7.41% and marking a 10.71% improvement over last year's $(0.28) per share loss.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:01 am

Eledon Pharmaceuticals (ELDN) and Acumen Pharmaceuticals (ABOS) experienced increased trading volume following a TipRanks article suggesting both 'Strong Buy' penny stocks could see over 300% gains according to analysts.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 3:42 pm

Acumen Pharmaceuticals has entered into a collaboration with Lonza for the manufacturing of Sabirnetug (ACU193), a potential treatment for Alzheimer's disease. This partnership covers both clinical development and future commercialization if the drug receives approval.

Portfolio Pulse from Benzinga Newsdesk

April 04, 2024 | 12:03 pm

HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Acumen Pharmaceuticals (NASDAQ:ABOS) with a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 1:22 pm

Acumen Pharmaceuticals shares dropped following the announcement of their Q4 earnings per share (EPS) results, which fell short of expectations.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 4:41 pm

Acumen Pharmaceuticals (NASDAQ:ABOS) reported Q4 earnings with losses of $(0.29) per share, missing the consensus estimate of $(0.26) by 11.54%. This represents a 9.38% improvement over the previous year's losses of $(0.32) per share.

Portfolio Pulse from Happy Mohamed

March 26, 2024 | 1:28 pm

Acumen Pharmaceuticals reported a fiscal year 2023 earnings per share (EPS) of $(1.08), a slight decrease from the previous year's $(1.06). The company also reported having $306.1 million in cash, cash equivalents, and marketable securities.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 11:08 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.